Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PNMT | P11086 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962008 | 0.83 | MEN1 (0.65) | MEN1KMT2APNMTMTNR1AMTNR1B | |
| SCHEMBL10324241 | 0.83 | MEN1 (0.65) | MEN1KMT2APNMTMTNR1AMTNR1B | |
| SCHEMBL6616489 | 0.80 | MEN1 (0.97) | MEN1KMT2APNMT | |
| SCHEMBL6634269 | 0.80 | MEN1 (0.57) | MEN1KMT2APNMTMTNR1AMTNR1B | |
| SCHEMBL5068043 | 0.77 | MEN1 (0.53) | MEN1KMT2APNMTADRA2AADRA2B | |
| SCHEMBL7237570 | 0.77 | MEN1 (0.53) | MEN1KMT2APNMTADRA2AADRA2B | |
| SCHEMBL14355729 | 0.76 | PNMT (0.69) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL13453377 | 0.76 | PNMT (0.69) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL172636 | 0.76 | PNMT (0.69) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL24420061 | 0.74 | MEN1 (0.48) | MEN1KMT2APNMTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | MEN1 1124/4885KMT2A 3949/4885PNMT 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.